Press release
Rare Kidney Diseases Market Current Scenario with Future Trends Analysis to 2031
Request A Sample:
https://www.insightaceanalytic.com/request-sample/1414
A condition known as rare kidney disease is characterized by non-functioning kidneys, which result in the accumulation of debris in the body and the development of health issues. A genetic or hereditary origin is frequently observed in this group of renal diseases, which are uncommon in the general population. Lupus nephritis, membranous nephropathy, focal segmental glomerular sclerosis, IgA nephropathy, and C3 glomerulopathy are among the primary target indications for rare kidney diseases. IgA nephropathy is a kidney disease that is distinguished by the accumulation of antibodies (IgA) in renal tissue, which can result in inflammation. A number of critical factors influence growth in the rare kidney disease market. It is expected that the proliferation of next-generation sequencing techniques will enhance the diagnostic accuracy of rare kidney diseases, facilitate genetic counseling, assist in the elucidation of the molecular mechanism of disease, and offer opportunities for carrier testing. The quality of life of patients is often sacrificed in exchange for a longer lifespan as a result of the increased accessibility and advancements in renal replacement therapy. The therapeutic advancements in rare kidney diseases have been influenced by a variety of factors, such as the absence of biomarkers to monitor disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not accurately reflect the underlying pathophysiological mechanisms. Complex studies and slow drug approvals will also impede market expansion.
List of Prominent Players in the Rare Kidney Diseases Market:
• GlaxoSmithKline,
• Recordati Rare Diseases,
• Amicus Therapeutics,
• Calliditas Therapeutics,
• Alexion Pharmaceuticals (A subsidiary of AstraZeneca),
• Travere Therapeutics,
• Aurinia Pharmaceutical,
• Advicenne,
• Protalix Biotherapeutics,
• AstraZeneca,
• Chinook Therapeutics,
• Reata Pharmaceuticals,
• Roche,
• Novartis Pharmaceuticals,
• Merk & co.,
• Apellis Pharmaceuticals,
• Omeros Corporation,
• Lonza
Market Dynamics:
Drivers-
Multiple factors contribute to the growth of the market for uncommon kidney diseases. The market has pushed itself by the expanding pipeline of treatments for uncommon kidney disease, which has recruited more than 21,630 individuals in clinical studies assessing these treatments at different stages of development. This rise may be ascribed to the significant surge in the occurrence rate of uncommon renal disorders worldwide. Consequently, this has led to an increase in the need for more efficient medications and treatments for uncommon kidney disorders, thereby propelling the growth of this field. Furthermore, to find biomarkers and improve the success rate of developing drugs for uncommon kidney disease, many technologies have been integrated to directly probe the affected organ, thereby feeding the growth of this market.
Curious About This Latest Version Of The Report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1414
Challenges:
Notwithstanding the prioritization of managing more prevalent illnesses that impact bigger populations in research funding and healthcare systems, the requirement for focused therapies required to successfully treat uncommon kidney disorders is often disregarded. Nevertheless, several persons globally are afflicted with uncommon kidney disorders. Furthermore, the market expansion has been hindered by the restricted accessibility of data regarding uncommon kidney diseases. This has led to many deficiencies in developing new research, healthcare strategies, and policy measures aimed at addressing the deficiencies in research and clinical care specifically focused on rare kidney diseases. The lack of awareness among physicians and patients about uncommon kidney disorders is an additional obstacle to the expansion of the industry.
Regional Trends:
The North America Rare Kidney Diseases market is expected to register a dominating market share in revenue metrics and is projected to grow at a high CAGR in the near future. The region's dominance can be attributed to the rise in the incidence rate of Fabry disease, lupus nephritis, nephropathic cystinosis, atypical hemolytic uremic syndrome, and other kidney related diseases. Governments and charitable trusts are expected to provide favorable funding for healthcare research, a surge in healthcare expenditure, early access to advanced technologies, and an increase in acceptance of technologically advanced products, all of which are expected to accelerate market development in North America during the forecast period. In addition, the European market for rare kidney diseases is significant for a variety of reasons. First and foremost, the demand for effective diagnostics and treatments is on the rise due to the increasing prevalence of rare renal diseases. Furthermore, genomic sequencing and personalized therapies have substantially enhanced the capacity to diagnose and treat these conditions, as a result of advancements in precision medicine.
Recent Developments:
• In August 2023, Novartis completed the purchase of US clinical-stage biopharmaceutical company Chinook Therapeutics. Chinook Therapeutics develops kidney-specific drugs. An initial $3.2 billion payment was made, with a possible $3.5 billion purchase value.
• In March 2024, Travere Therapeutics, Inc. filed a sNDA to the FDA to convert FILSPARI® (sparsentan)'s expedited approval in IgAN to full approval. FILSPARI, the first and only non-immunosuppressive medication to treat kidney glomerular degeneration and proteinuria in primary IgAN patients at risk of fast disease progression, received expedited FDA clearance in February 2023.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1414
Segmentation of Rare Kidney Diseases Market-
By Target Indication-
• IgA Nephropathy
• Lupus Nephritis
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• C3 Glomerulopathy
• Cystinosis
• Dense Deposit Disease
• Distal Renal Tubular Acidosis
• Fabry Disease
• Refractory Gout
• Atypical Hemolytic Uremic Syndrome
• Others
By Type of Molecule-
• Small Molecules
• Biologics
o Monoclonal Antibody
o Hormone
o Recombinant Protein
o Others
By Route of Administration-
• Oral
• Intravenous
• Subcutaneous
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Get more information:
https://www.insightaceanalytic.com/report/global-rare-kidney-diseases-market-/1414
Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rare Kidney Diseases Market Current Scenario with Future Trends Analysis to 2031 here
News-ID: 3881101 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
4PL Logistics Market Revenue Report with Forecast to 2034
"4PL Logistics Market" in terms of revenue was estimated to be worth $59.6 Billion in 2024 and is poised to reach $133.3 Billion by 2034, growing at a CAGR of 8.5% from 2025 to 2034 according to a new report by InsightAce Analytic.
Get Free Sample Report @
https://www.insightaceanalytic.com/request-sample/1609
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global 4PL Logistics Market are:
• Rapid growth of automotive the…
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Heavy-Duty Autonomous Vehicle Market- (By Application (Logistics, Public Transportation, Construction and Mining, Others), By Propulsion Type (Internal Combustion Engine Vehicles, Electric Vehicles), By Vehicle Type (Heavy Trucks, Heavy Buses, Roboshuttles), By Level of Autonomy (Fully Autonomous Vehicles, Semi-Autonomous Vehicles), By Sensor Type (LiDAR, RADAR, Camera, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According…
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-Commerce Logistics Market Size, Share & Trends Analysis Report By Service Type (Transportation And Warehousing) And Operational Area (International And Domestic)- Market Outlook And Industry Analysis 2034"
The global e-commerce logistics market is estimated to reach over USD 5340.2 billion by 2034, exhibiting a CAGR of 26.4% during the forecast period.
Request For Free Sample Pages:…
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-bikes Market Size, Share & Trends Analysis Report By Class (Class-I, Class-II, Class-III), Speed (Up to 25km/h, 25-45 km/h), Battery Type (Lithium-ion, Lithium-ion Polymer, Lead Acid), Mode (Pedal Assist, Throttle), Component (batteries, electric motors, frames with forks, wheels, crank gears, brake systems and motor controllers) , Motor Type (hub and mid), Usage (mountain, trekking, city/urban,…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
